Objective: To investigate the relationship between the clinical and pathological findings in IgA nephropathy with or without IgG deposition in the glomerular mesangial area.
Methods: The data were collected from 122 patients with a diagnosis of IgA nephropathy by renal biopsy in the Third Affiliated Hospital of Southern Medical University between November, 2009 and February, 2016. All the samples were examined by light microscopy, immunofluorescence and electron microscopy. According to the results of immunofluorescence assay, the patients were divided into IgA group (n=63) and IgA-IgG group (n=59). The pathological classification of IgA nephropathy was analyzed according to Oxford classification and Lee's classification. The clinical and pathological findings were compared between the two groups.
Results: Compared with the patients with IgA nephropathy but without IgG deposition, patients with IgA nephropathy with IgG deposition had higher serum creatinine, higher 24-h urine protein, higher blood uric acid, higher triglyceride levels (P<0.05) and lower eGFR (P<0.05); more of these patients were in Lee's grade IV-V, had renal tubular atrophy and/or interstitial fibrosis, and had MEST scores more than 3 (P<0.05).
Conclusion: Patients with IgA nephropathy with IgG deposition in the glomerular mesangial have severer clinical symptoms and more serious pathological changes. Measures should be taken to control IgG deposition in patients with IgA nephropathy to delay the progress of the disease.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780451 | PMC |
http://dx.doi.org/10.3969/j.issn.1673-4254.2017.03.05 | DOI Listing |
CEN Case Rep
December 2024
Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Minato-Ku, Tokyo, 105-8461, Japan.
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide with heterogeneous histopathological phenotypes. Although IgAN with membranoproliferative glomerulonephritis (MPGN)-like features has been reported in children and adults, treatment strategies for this rare IgAN subtype have not been established. Here, we present the case of a 56-year-old man with no history of kidney disease who initially presented with nephrotic syndrome.
View Article and Find Full Text PDFCEN Case Rep
December 2024
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Neuron-derived neurotrophic factor (NDNF) was discovered as a target antigen in membranous nephropathy (MN) caused by syphilis. However, there have been few reports of NDNF-positive MN in Japan. A 19-year-old female patient was admitted to our hospital with nephrotic syndrome and acute kidney injury.
View Article and Find Full Text PDFSci Rep
December 2024
Department of Nephrology, General Hospital of Ningxia Medical University, Yinchuan, China.
Metabolic syndrome, a cluster of conditions including obesity, hyperglycemia, hypertension, and dyslipidemia, is increasingly recognized for its association with kidney disease. However, the impact of metabolic syndrome on the long-term prognosis of IgA nephropathy(IgAN) remains understudied. From August 2009 to December 2018, we conducted a retrospective cohort study at the Department of Nephrology, General Hospital of Ningxia Medical University, involving 698 patients with primary IgAN identified by the initial renal biopsy.
View Article and Find Full Text PDFClin Exp Nephrol
December 2024
Department of Nephrology, Ningbo Yinzhou Second Hospital, No. 998, North Qianhe Road, Yinzhou District, Ningbo City, 315000, Zhejiang Province, China.
Purpose: The study aimed to evaluate the efficacy and safety of rituximab (RTX) in primary IgA nephropathy (IgAN).
Methods: A retrospective review was conducted on the medical records of 22 patients diagnosed with primary IgAN who received RTX treatment. The clinical data, including blood tests, urine examinations and estimated glomerular filtration rate (eGFR), were analyzed at four time point: baseline, 3 months, 6 months and 12 months.
Background: There is a lack of evidence to suggest that outcomes of adolescent and adult-onset glomerular disease differ. Still, most glomerular disease trials include adults but exclude adolescents.
Methods: We designed a retrospective study using the CureGN database to compare individuals with adolescent-onset glomerular disease relative to individuals with older and younger age at onset.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!